Thelansis

Malignant Pleural Mesothelioma (MPM) Market Outlook Thelansis’s “Malignant Pleural Mesothelioma (MPM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Malignant Pleural Mesothelioma (MPM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the grea...

Malignant Pleural Mesothelioma (MPM) Market Outlook Thelansis’s “Malignant Pleural Mesothelioma (MPM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Malignant Pleural Mesothelioma (MPM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Malignant Pleural Mesothelioma (MPM) Overview Malignant pleural mesothelioma (MPM) is a highly aggressive cancer affecting the pleural surface, often stemming from prior asbestos exposure, typically manifesting around 40 years after initial fiber exposure. The majority of MPM patients initially present with breathlessness, chest pain, or both. Early-stage breathlessness typically stems from pleur...

Malignant pleural mesothelioma (MPM) is a highly aggressive cancer affecting the pleural surface, often stemming from prior asbestos exposure, typically manifesting around 40 years after initial fiber exposure. The majority of MPM patients initially present with breathlessness, chest pain, or both. Early-stage breathlessness typically stems from pleural effusion, evident in 70% of patients at presentation. However, as the disease progresses, pleural effusions tend to decrease, either due to medical intervention or obliteration of the pleural space by the tumor. Additional symptoms may include fatigue, anorexia, weight loss, sweats, and malaise. Histologically, MPM presents in four main sub-types: epithelioid, sarcomatoid, biphasic or mixed, and desmoplastic. The sarcomatoid variant is notably associated with the poorest outcomes, boasting a median survival of only 4 months. In contrast, the epithelioid sub-type offers the most promising prognosis, with a median survival of 13.1 months....

  Malignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleural surface, predominantly caused by prior asbestos exposure. Most MPM cases are caused by exposure to asbestos, often occurring >40 years previously. Prognosis with MPM is poor, and median survival ranges from 8 to 14 months after diagnosis. Women have a better prognosis than men, but due to the occupational nature of the disease, there is a 4:1 male predominance. The four major histological subtypes are Sarcomatoid, epithelioid, biphasic or mixed, and desmoplastic. The sarcomatoid variant is associated with the worst outcomes, with a four-month median survival.   The incidence of malignant pleural mesothelioma (MPM) ranges between 9 to 23 points per MN elderly patient with a man and women of 5:1.2.   The competitive landscape of Malignant Pleural Mesothelioma (MPM) includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelera...